# A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines

> **NCT03580369** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 1072 (actual)

## Conditions studied

- Chronic Spontaneous Urticaria

## Interventions

- **BIOLOGICAL:** Ligelizumab
- **BIOLOGICAL:** Omalizumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03580369
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-17
- **Primary completion:** 2021-07-16
- **Final completion:** 2022-06-14
- **Target enrollment:** 1072 (ACTUAL)
- **Last updated:** 2023-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03580369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03580369, "A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT03580369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*